Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc. develops clinical-stage cancer diagnostics centered on proprietary molecular testing for screening, treatment planning, and monitoring. Its news commonly covers the MSC test, a non-invasive blood-based MicroRNA Signature Classifier that analyzes 24 circulating microRNAs to classify lung nodules by malignancy risk in lung cancer screening workflows.
Company updates also include StemPrintER studies in breast cancer, collaborations with diagnostic and clinical research organizations, blood-sample access agreements, testing infrastructure for microRNA extraction, investor presentations, and board-level share purchase announcements. These developments reflect AccuStem’s focus on cancer biology, including tumor stemness, and on translating molecular assays into clinical diagnostic use.
AccuStem Sciences (OTCQB: ACUT) executed a pilot study agreement with NSABP to evaluate the StemPrintER test in a subset of patients from the NSABP B-32 cohort. StemPrintER interrogates 20 genes to stratify early-stage breast cancer patients by tumor "stemness" to assess recurrence risk. Prior studies cited show "High Stemness" patients are up to 4x more likely to experience distant recurrence than "Low Stemness" patients. The pilot will assess sample viability and predictive utility in the surgical setting and enable subsequent confirmation across the full B-32 cohort of over 5,000 enrolled patients.
AccuStem Sciences (OTCQB: ACUT) announced an expansion of blood-based testing capabilities through its partnership with EmeritusDX. The collaboration includes the installation of the Promega Maxwell RSC system at EmeritusDX for high-throughput microRNA extraction from blood samples.
This expansion will support AccuStem's MSC test, the first diagnostic using microRNAs to stratify lung nodules for malignancy risk. Additionally, EmeritusDX has increased its sales force by 35% and launched the Syntara™ platform for personalized treatment strategies in hematologic diseases.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer outcomes, has announced that CEO Wendy Blosser will present at the Life Sciences Virtual Investor Forum on September 18th, 2025 at 2:30 PM EST.
The interactive online presentation will showcase AccuStem's product portfolio, which focuses on innovative molecular testing and tumor "stemness" analysis for cancer screening, treatment, and monitoring. Investors can participate in real-time Q&A and schedule one-on-one meetings from September 19-24. An archived webcast will be available for those unable to attend live.
AccuStem Sciences (OTCQB: ACUT) and EmeritusDX have expanded their strategic partnership to commercialize the MSC test for lung cancer screening. The test analyzes 24 microRNAs to differentiate between high and low-risk lung nodules identified through low-dose computed tomography (LDCT).
The partnership aims to enhance lung nodule stratification accuracy, improve patient outcomes, and reduce healthcare costs. The companies plan to launch the MSC test in US clinics in 2026, targeting the 1.6 million patients diagnosed annually with lung nodules in the United States.
The collaboration will utilize EmeritusDX's CLIA-certified laboratory and commercial infrastructure alongside AccuStem's cancer screening technologies. Both companies will pursue reimbursement strategies to broaden access to the MSC test.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased an additional 5,000 shares of ACUT stock in the open market. This acquisition increases Cerrone's total holdings to 4,915,759 shares of the company.
AccuStem Sciences (OTCQB: ACUT) has signed a development agreement to access blood samples from the Rete Italiana di Screening Polmonare (RISP) clinical trial for its microRNA Signature Classifier (MSC) test development. The trial spans 18 centers in Italy.
The MSC test analyzes 24 miRNAs in plasma samples from patients with lung nodules to enhance low dose computed tomography (LDCT) screening accuracy. The MILD trial showed that combining MSC with LDCT could reduce false positive rates by a factor of five. The test has been validated across 5,000+ patients in multiple prospective trials.
The agreement includes statistical and analytical support to help AccuStem establish and commercialize the MSC test in the US, with a planned launch in 2026. The technology aims to improve patient triage, enhance outcomes, and reduce healthcare costs when used in conjunction with LDCT screening.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased 38,000 additional company shares in the open market. This acquisition increases Cerrone's total holdings to 4,910,759 shares.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Board Chairman Gabriele Cerrone has increased his stake in the company. The Chairman purchased 152,802 additional ACUT shares through open market transactions, bringing his total shareholding to 4,872,759 shares.